Hereditary Angioedema - A Pipeline Analysis Report

This pipeline analysis report provides detailed insights into the drug development landscape of the development of drug for hereditary angioedema including molecules at pre-clinical, discovery, and other developmental stages. The report also offers comprehensive information about the therapeutic assessment of the pipeline molecules based on various segmentations such as indications coverage, therapies employed, route of administration, therapeutic modality, targets for drug development, and mechanism of action.

Overview of the drug development pipeline for hereditary angioedema

Hereditary angioedema (HAE) is a genetic disorder and is also known as angioedema. It is resulted from low level of plasma protein C1 inhibitor that causes swelling of hand, skin, and feet. One out of 50,000 people are estimated to be affected by HAE, in which, Type III is very rare and accounts for 1%, Type II for 15%, and Type I for 84-85%. Patients suffering from this condition experience various symptoms including muscle aches, abdominal pain, problem in breathing, and headache and vomiting. Technavio’s market research analysts have predicted that with the introduction of prophylactic treatment as one of the most promising approach to treat hereditary angioedema, the global hereditary angioedema market will witness growth in the forthcoming years.

According to this pipeline analysis report, most of the drug development molecules in the pipeline are under the pre-clinical development stage. For instance, sponsors such as Adverum Biotechnologies developed ADVM-053 and Alnylam Pharmaceuticals developed ALN-F12, which are under the pre-clinical stage. Our market research analysts have also identified that a small amount of drug molecules that are being developed comes under the phase III, and phase II, and discovery stages. The pipeline landscape in the pipeline analysis report mentions the percentage of drug development molecules that are under the phase I stage.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of drug molecules for the treatment of hereditary angioedema. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are –

• CEVEC
• CSL Behring
• Ionis Pharmaceuticals

Therapeutic assessment of the drug development pipeline for hereditary angioedema by route of administration

• Subcutaneous
• Oral
• Intravenous

The subcutaneous route of administration (ROA) involves the administration of drug substances directly into the tissue layer between the skin and muscle mostly with a short needle. It has been observed that the majority of total therapeutics are being developed for subcutaneous administration.

Therapeutic assessment of the drug development pipeline for hereditary angioedema by therapeutic modality

• Biomolecule
• Small molecule

According to this pipeline analysis report, the majority of molecules that are currently in the drug development pipeline for hereditary angioedema are being developed as biomolecules. Biomolecule plays a significant role in the maintenance and metabolic processes of living organisms.

Key questions answered in the report include

• What are the drug development molecules in the various development stages for hereditary angioedema?
• What are the companies that are currently involved in the development of drug development molecules for hereditary angioedema?
• Insight into discontinued/inactive molecules with appropriate reasoning?
• What are the major regulatory authorities approving drugs in various regions?
• Detailed profiling of each active molecule

Technavio also offers customization on reports based on specific client requirement.